These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 599799)

  • 41. [Anti-arrhythmic and hemodynamic effects of visken and glucagon in rhythm disorders in the acute phase of myocardial infarct].
    Golikov AP; Orlov AI; Ivleva VI; Stepura OB
    Kardiologiia; 1980 Oct; 20(10):35-40. PubMed ID: 6108378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Beta-blockader, pindolol, in the therapy of angina pectoris; a report on a multicentric controlled study].
    Lang E; Fitscha P; Schiess W
    Wien Med Wochenschr; 1979 Sep; 129(17):484-8. PubMed ID: 120078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension.
    Brecht HM; Banthien F; Schoeppe W
    Klin Wochenschr; 1976 Nov; 54(22):1095-105. PubMed ID: 1003867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evaluation of the therapeutic efficacy of a fixed combination of beta blockader and diuretic, in the treatment of systemic arterial hypertension. A multicenter study].
    Zilenovski AM; Freire CA; Iverson MT
    Arq Bras Cardiol; 1984 Jun; 42(6):435-41. PubMed ID: 6393921
    [No Abstract]   [Full Text] [Related]  

  • 45. [Visken in the treatment of arterial hypertension].
    Sznajderman M; Brym E
    Pol Tyg Lek; 1975 Dec; 30(50):2105-7. PubMed ID: 1197105
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of hypertension with a combination of prindolol and clopamide (author's transl)].
    Gábor G; Jávor T; Szám I; Török E
    MMW Munch Med Wochenschr; 1975 Nov; 117(46):1853-6. PubMed ID: 811982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Quantitative data on the additive effect of a beta-receptor blockader and a saluretic in the therapy of hypertension. Interindividual-component comparison in a doble-blind study].
    Werning C; Hammerschmidt D; Kaiser Hj
    Med Welt; 1978 Oct; 29(40):1570-5. PubMed ID: 703579
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of the beta-receptor blocking agent visken on blood pressure of hypertensive patients, on plasma renin activity and electrolytes.
    Sonkodi S; Pap A; Varró V
    Ther Hung; 1976; 24(2):60-2. PubMed ID: 982340
    [No Abstract]   [Full Text] [Related]  

  • 49. [Evaluation of beta-adrenolytic treatment of essential hypertension with the use of visken (author's transl)].
    Lukasik S; Halawa B; Surowiak M; Kasprzak J
    Przegl Lek; 1978; 35(7):637-41. PubMed ID: 715242
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of hypertension with a new beta-blocking agent, pindolol (Visken).
    Persson I; Ulrich J
    Eur J Clin Pharmacol; 1973 Dec; 6(4):217-9. PubMed ID: 4591149
    [No Abstract]   [Full Text] [Related]  

  • 51. [Hemodynamic evaluation of pindolol].
    Biffani G; Santini M
    Minerva Cardioangiol; 1976 Sep; 24(9):613-8. PubMed ID: 1012501
    [No Abstract]   [Full Text] [Related]  

  • 52. A comparison of propranolol and prindolol in the treatment of essential hypertension.
    Beaton GR; Rosendorff C; Kramer R; Simpson RD
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):268-74. PubMed ID: 4208340
    [No Abstract]   [Full Text] [Related]  

  • 53. [Lowering of the blood pressure and renin suppression by beta receptor blockade with Visken in patients with borderline hypertension (author's transl)].
    Werning C
    Med Klin; 1973 Nov; 68(47):1559-63. PubMed ID: 4781097
    [No Abstract]   [Full Text] [Related]  

  • 54. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
    Persson I
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):91-3. PubMed ID: 786690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of supraventricular arrhythmias using the beta-blockader Visken].
    Zdichynec B
    Z Arztl Fortbild (Jena); 1977 May; 71(10):478. PubMed ID: 910468
    [No Abstract]   [Full Text] [Related]  

  • 56. Labetalol and pindolol in the treatment of hypertension: a comparative study.
    Romo M; Halttunen P; Saarinen P; Sarna S
    Ann Clin Res; 1979 Dec; 11(6):249-52. PubMed ID: 398184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased plasma noradrenaline concentrations in essential hypertension and their decrease after long-term treatment with a beta-receptor-blocking agent (prindolol).
    Brecht HM; Banthien F; Ernst W; Schoeppe W
    Clin Sci Mol Med Suppl; 1976 Dec; 3():485S-488S. PubMed ID: 1071667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of pindolol (Visken) on plasma and blood volume in men with primary arterial hypertension].
    Wyrzykowski B; Suchecka-Rachoń K
    Pol Tyg Lek; 1985 Sep; 40(38):1083-6. PubMed ID: 3906604
    [No Abstract]   [Full Text] [Related]  

  • 59. [Therapy of anginose disorders using the combination beta blockader Prindolol and isosorbide dinitrate. A comparative double-blind cross-over study].
    Szám I; Kerkovits G; Buday G
    Med Monatsschr; 1974 Sep; 28(9):400-3. PubMed ID: 4608972
    [No Abstract]   [Full Text] [Related]  

  • 60. [Hemo- and cardiodynamic changes in arterial hypertension patients as affected by alpha- and beta-adrenergic blockader therapy].
    Zonis BIa
    Kardiologiia; 1981 Mar; 21(3):28-32. PubMed ID: 6112285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.